ARVINAS INC. DL-,001

Arvinas reported Q1 2026 revenue of $15.6 million (estimate $17.16 million, Q1 2025: $188.8 million), mainly due to the restructuring of the partnership with Pfizer. Earnings per share were -$0.90, beating the expected -$0.93. The company significantly cut R&D and general & administrative expenses, extended its cash runway into the second half of 2028, and points to FDA approval for VEPPANU as a key milestone. The stock rose 1.45% in premarket trading to $9.80. » Más en de.investing.com

Arvinas and Pfizer received from Rigel the exclusive global rights to develop, manufacture and commercialize VEPPANU (vepdegestrant) for ER-positive, HER2-negative, ESR1-mutant advanced breast cancer. The agreement provides for an upfront payment of $70 million plus $15 million upon completion of certain transition activities, in addition to up to $320 million in milestones and tiered royalties in the mid-teens to mid-twenties percent range. Rigel will handle launch and commercialization in the U.S. and retains global rights with options to grant sublicenses outside the U.S. Arvinas reported Q1 EPS of -$0.90 and said its cash runway extends into the second half of 2028; closing of the transaction is subject to regulatory approvals. » Más en de.investing.com

The FDA has approved VEPPANU (vepdegestrant) for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced/metastatic breast cancer after at least one line of endocrine therapy. The approval is considered the first for a PROTAC protein degrader and was granted ahead of the PDUFA date of June 5, 2026. After trading resumed, the Arvinas share rose intraday by up to 13%. » Más en de.investing.com